Skip to main content
. 2020 Apr 16;59(14):1695–1704. doi: 10.2169/internalmedicine.4298-19

Table 1.

The Clinical Characteristics and Laboratory Findings of the Enrolled Patients.

Characteristics All patients (n=59)
Mean±SD or n (%)
Age (years) 66.1±10.7
Sex (Man/Woman) 36/23
BMI (kg/m2) 24.0±4.7
BMI>25 19 (32.2)
Number of cases with reduced muscle volume 10 (16.9)
Etiology
HBV 4 (6.8)
HCV 24 (40.7)
Alcohol 17 (34.7)
NASH 6 (10.2)
others 8 (13.6)
Child-Pugh score 6.8±2.1
Child-Pugh classification (A/B/C) 37/14/8
MELD score 9.3±4.8
Complication
HCC 31 (52.5)
Ascites 12 (20.3)
Number of cases using BCAA supplementation 27 (45.8)
BCAA granules, three sachets daily 13 (22.0)
BCAA powder mix, one/two/three packages daily 11 (18.6)/1 (1.7)/2 (3.4)
Concomitant medications
Lactulose 5 (8.5)
Antibiotics 5 (8.5)
Zinc sulfate 3 (5.1)
L-Carnitine 0 (0.0)
Molecular-targeted agents for HCC 0 (0.0)
<Laboratory findings>
ALT (U/L) 39.1±31.2
Albumin (g/dL) 3.4±0.5
Total-bilirubin (mg/dL) 1.5±1.1
Platelet (×104/μL) 11.5±5.9
Prothrombin time (%) 73.3±17.0
Na (mmol/L) 139.4±3.0
NH3 (μg/dL) 56.2±27.4
CRP (mg/dL) 0.44±0.64
Amino acids, standard value
Valine (nmol/L), 158.4-287.7 212.6±57.4
Leucine (nmol/L), 80.9-154.3 113.7±35.5
Isoleucine (nmol/L), 41.3-84.9 64.2±19.3
Methionine (nmol/L), 19.2-32.7 37.0±14.3
Tyrosine (nmol/L), 50.2-82.6 106.3±31.1
Phenylalanine (nmol/L), 45.7-76.5 88.3±26.6
Histidine (nmol/L), 67.9-97.1 88.9±15.8
Tryptophan (nmol/L), 41.4-65.5 50.5±14.6
Ornithine (nmol/L), 43.2-95.7 99.5±31.2
Lysine (nmol/L), 118.7-257.0 177.1±44.4
Arginine (nmol/L), 46.0-121.7 80.3±28.4
BTR 3.9±1.6

SD: standard deviation, BMI: body mass index, HBV: hepatitis B virus, HCV: hepatitis C virus, NASH: nonalcoholic steatohepatitis, MELD score: model for end-stage liver disease score, HCC: hepatocellular carcinoma, BCAAs: branched-chain amino acids, ALT: alanine transaminase, Na: serum sodium, NH3: serum ammonia, CRP: C-reactive protein, BTR: branched-chain amino acid to tyrosine ratio